Nestlé Health Science, a subsidiary of Nestlé (NESN.VX), added to its portfolio of nutrition solutions, diagnostics, devices and drugs last week.
The company paid $120 million to Seres Therapeutics (NASDAQ: MCRB) to develop and commercialize its product candidates now in development for the treatment of clostridium difficile (c-diff) infection and inflammatory bowel disease (IBD), outside the United States and Canada.
The agreement supports the expansion of Seres’ portfolio in markets outside of the United States and Canada and gives financial support for its ongoing R&D.
Seres retains full commercial rights to its entire portfolio of product candidates in the United States and Canada, where the company plans to build its own commercial organization. This is Nestle’s third investment in the company in the past 12 months.